Quality Control (QC) in Clinical Research

Detail-oriented QC that delivers well-formatted, accurate, and consistent regulatory documents every time.

Thank you for the excellent QC, which gives us great comfort in the quality of the final document.
Medical Writing Director
Midsize Pharma Sponsor

QC services at MMS come complete with innovative, streamlined processes to ensure the creation of high-quality documents, delivered on-time with fewer drafts. This eases document development for Sponsor study teams and keeps their programs running at full-strength.

With fast and adaptive QC timelines, a global presence in multiple time zones, and a commitment to quality, you can expect the highest level of satisfaction for every project.

Accurate & Consistent QC Reviews

MMS provides QC as a service (QCAS) on documents we author, or as a stand-alone service. We employ a robust QC process that operates effectively or can be adapted to meet Sponsor-specific requirements. This design ensures the accuracy and consistency of data within any clinical or scientific document.

Additionally, we check documents against templates and style guides for proper formatting and style points. Using our proven method, we can QC any clinical, non-clinical, or scientific document quickly and efficiently. Our deep expertise in QCing medical writing deliverables expands across nearly all therapeutic areas.

The MMS QC Group has expertise in a broad range of regulatory documents, including:

  • Core documents, such as clinical study protocols, informed consent forms (ICF), clinical study reports (CSR), aggregate reports and common technical document (CTD) modules
  • Less common documents, such as briefing packages and responses to global health authority questions
  • Unique documents provided by Sponsors that need bespoke QC review
24-Hour Global QC Coverage

MMS is flexible across numerous times zones. With team members across India, South Africa, and the US, we can accommodate tight timelines and short notice. Our team meets daily to properly resource the best fit team member for each document type or therapeutic area.

We have the ability to train and grow new team members quickly to accommodate a growing number of requests.

MMS Standalone QC Request Portal

To further improve your experience with MMS’ QC service, we have developed a QC web portal to allow you to book your standalone QCs using unique login credentials issued to you by MMS IT. Requesting your standalone QCs through the portal is fast and simple, gives you complete visibility of your current and past requests, ability to check on the status of ongoing QCs or edit your requests in any way, upload new sources and documents for QC, and download your completed QC files from the portal.

The portal sends you a notification email at each step of the process to keep you actively appraised of the QC’s progress, including one when the QC is complete which contains a download link so that you don’t need to visit the portal to collect your QCd document, should you choose.

The portal is secure so that only you can see your QCs, and anyone at your institution with portal credentials can view all of your institution’s requests.

If you are an MMS client and are interested in our standalone QC service and would like a demonstration of the portal, please speak with your MMS project manager, who will be happy to arrange that for you.

Suggested For You

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium